VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).

被引：0
|
作者：
King, M. [1 ]
Stockler, M. [2 ]
O'Connell, R. [2 ]
Joly, F. [3 ]
Lanceley, A. [4 ]
Hilpert, F. [5 ]
Okamoto, A. [6 ]
Aotani, E. [7 ]
Pignata, S. [8 ]
Donnellan, P. [9 ]
Oza, A. [10 ]
Avall-Lundqvist, E. [11 ]
Berek, J. [12 ]
Buizen, L. [2 ]
Sjoquist, K. [2 ]
Butow, P. [1 ]
Friedlander, M. [13 ]
Gillies, K. [2 ]
Martyn, J. [2 ]
机构：
[1] Univ Sydney, Psychooncol Res Grp, Sydney, NSW 2006, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Ctr Francoise Baclesse, GINECO, Caen, France
[4] UCL, London, England
[5] Klin Gynakol & Gerburtshilfe, UKSH, Kiel, Germany
[6] Jikei Univ, Sch Med, Tokyo, Japan
[7] Kitisato Acad Res Org, Tokyo, Japan
[8] Natl Canc Inst, Naples, Jamaica
[9] Galway Univ Hosp, Galway, Ireland
[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[11] Linkoping Univ, NSGO, Linkoping, Sweden
[12] Stanford Womens Canc Ctr, Stanford, CA USA
[13] Prince Wales Hosp, ANZGOG, GCIG Symptom Benefit StudyGrp GCIG, Kingston, ON, Canada
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1157
引用
收藏
页码：457 / 458
页数：2
相关论文
共 41 条
  • [21] CA125-related Measures of Tumor Kinetics and Outcome of Patients with Recurrent Ovarian Cancer Receiving Chemotherapy: A Retrospective Evaluation
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Coccorullo, Zaira
    Ratti, Riccardo
    Caltabiano, Graziano
    Guarneri, Domenico
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (12) : 1203 - 1209
  • [22] Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study
    Wenzel, Lari
    Huang, Helen Q.
    Cella, David
    McKinney, Chelsea O.
    Zevon, Michael A.
    LaChance, Jason A.
    Walker, Joan L.
    Salani, Ritu
    Modesitt, Susan C.
    Morris, Robert T.
    Bradley, William H.
    Boente, Matthew P.
    von Gruenigen, Vivian E.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 392 - 397
  • [23] HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome
    Fagotti, Anna
    Costantini, Barbara
    Vizzielli, Giuseppe
    Perelli, Federica
    Ercoli, Alfredo
    Gallotta, Valerio
    Scambia, Giovanni
    Fanfani, Francesco
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 221 - 225
  • [24] Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer
    Nakamura, Keiichiro
    Nagasaka, Takeshi
    Nishida, Takeshi
    Haruma, Tomoko
    Ogawa, Chikako
    Kusumoto, Tomoyuki
    Seki, Noriko
    Hiramatsu, Yuji
    ONCOLOGY LETTERS, 2016, 11 (06) : 3975 - 3981
  • [25] Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer
    Sebastian, Martin
    Ryden, Anna
    Walding, Andrew
    Papadimitrakopoulou, Vassiliki
    LUNG CANCER, 2018, 122 : 100 - 106
  • [26] Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
    Cohen, Paul A.
    Webb, Penelope M.
    King, Madeleine
    Obermair, Andreas
    Gebski, Val
    Butow, Phyllis
    Morton, Rachael
    Lawson, Wanda
    Yates, Patsy
    Campbell, Rachel
    Meniawy, Tarek
    McMullen, Michelle
    Dean, Andrew
    Goh, Jeffrey
    McNally, Orla
    Mileshkin, Linda
    Beale, Philip
    Beach, Rhonda
    Hill, Jane
    Dixon, Cyril
    Hegarty, Sue
    Codde, Jim
    Ives, Angela
    Lee, Yeh Chen
    Brand, Alison
    Mellon, Anne
    Bilic, Sanela
    Black, Isobel
    Jeffares, Stephanie
    Friedlander, Michael
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 560 - 565
  • [27] Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study
    Gadducci, Angiolo
    Cosio, Stefania
    Landoni, Fabio
    Lissoni, Andrea Alberto
    Zola, Paolo
    Laudani, Maria Elena
    Ardizzoia, Antonio
    Gambino, Angela
    Sartori, Enrico
    ANTICANCER RESEARCH, 2022, 42 (04) : 2017 - 2022
  • [28] Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy
    Kleinman, Leah
    Benjamin, Katy
    Viswanathan, Hema
    Mattera, Maria Stoeckl
    Bosserman, Linda D.
    Blayney, Douglas W.
    Revicki, Dennis
    BLOOD, 2008, 112 (11) : 250 - 250
  • [29] DEVELOPMENT OF A NOVEL PATIENT-REPORTED OUTCOME (PRO) MEASURE TO ASSESS HORMONAL-BASED TREATMENT SYMPTOMS AND THEIR IMPACTS IN PATIENTS WITH PROSTATE CANCER
    Chladek, M.
    Hunsche, E.
    Hudgens, S.
    Brown, B.
    Fallick, M.
    dePaauw-Holt, S.
    Cox, K.
    Ross, A.
    VALUE IN HEALTH, 2022, 25 (07) : S573 - S574
  • [30] Development and validation of a patient reported outcome measure for health-related quality of life for locally recurrent rectal cancer: a multicentre, three-phase, mixed-methods, cohort study
    Harji, Deena P.
    Koh, Cherry
    McKigney, Niamh
    Solomon, Michael J.
    Griffiths, Ben
    Evans, Martyn
    Heriot, Alexander
    Sagar, Peter M.
    Velikova, Galina
    Brown, Julia M.
    ECLINICALMEDICINE, 2023, 59
12345